论文部分内容阅读
目的评价阿德福韦酯联合胸腺肽治疗慢性乙性肝炎的疗效,探讨两者治疗的协同作用。方法将207例HBV DNA及HbeAg阳性的患者随机分成两组,A组采用阿德福韦酯联合胸腺肽治疗,B组采用阿德福韦酯单独治疗。A组在阿德福韦酯组治疗基础上加用胸腺肽1.6mg皮下注射,2次/周,连用48周;B组给予阿德福韦酯10mg/d,连用48周。结果与结论阿德福韦酯联合胸腺肽治疗慢性乙性肝炎疗效明显优于阿德福韦酯单独治疗,具有显著的抗炎和抗病毒作用,在整体治疗慢性乙肝方面具有一定的优势,是慢性乙肝患者安全经济有效的治疗方法。
Objective To evaluate the efficacy of adefovir dipivoxil combined with thymosin in the treatment of chronic hepatitis B and to explore the synergistic effect of the two treatments. Methods 207 cases of HBV DNA and HbeAg positive patients were randomly divided into two groups, A group treated with adefovir dipivoxil combined with thymosin, B group treated with adefovir dipivoxil alone. Group A was treated with adefovir dipivoxil by subcutaneous injection of thymosin 1.6mg twice a week for 48 weeks. Group B was given adefovir dipivoxil 10mg / d for 48 weeks. Results and Conclusion Adefovir dipivoxil combined with thymosin in the treatment of chronic hepatitis B was significantly better than adefovir dipivoxil alone treatment, with significant anti-inflammatory and anti-viral effects in the overall treatment of chronic hepatitis B has some advantages, is chronic Hepatitis B patients safe and cost-effective treatment.